Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
1,173 questions in 89 reviews · Neuromuscular
current versionsNo studies 302 · 25.7%Ungraded 119 · 10.1%Very low 267 · 22.8%Low 239 · 20.4%Moderate 177 · 15.1%High 69 · 5.9%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Endoscopic vs open or mini‐open carpal tunnel release Time to return to work (in days) · participants with carpal tunnel syndrome Endoscopic release for carpal tunnel syndrome (2014) · Cochrane | no estimate extracted | 4 studies · 274 participants | Very low |
Endoscopic vs open or mini‐open carpal tunnel release Major complications (events) · participants with carpal tunnel syndrome Endoscopic release for carpal tunnel syndrome (2014) · Cochrane | RR 1 [0.38, 2.64] | 15 studies · 1508 participants | Low |
Hydroxytryptophan vs placebo Short‐term (within 1 month) percentage change (improvement) in overall speech production · people with speech disorder resulting from hereditary ataxias Treatment for speech disorder in Friedreich ataxia and other hereditary ataxia syndromes (2014) · Cochrane | no estimate extracted | 0 studies · 0 participants | Ungraded |
Thyrotropin‐releasing hormone tartrate vs placebo Short‐term (1 week) change in quality of life scores related to communication as measured by validated communication assessments · people with speech disorder resulting from hereditary ataxia Treatment for speech disorder in Friedreich ataxia and other hereditary ataxia syndromes (2014) · Cochrane | no estimate extracted | 0 studies · 0 participants | Ungraded |
Thyrotropin‐releasing hormone tartrate vs placebo Longer‐term (minimum 1 month) change in generic quality of life scores · people with speech disorder resulting from hereditary ataxia Treatment for speech disorder in Friedreich ataxia and other hereditary ataxia syndromes (2014) · Cochrane | no estimate extracted | 0 studies · 0 participants | Ungraded |
Thyrotropin‐releasing hormone tartrate vs placebo Adverse effects (during study) · people with speech disorder resulting from hereditary ataxia Treatment for speech disorder in Friedreich ataxia and other hereditary ataxia syndromes (2014) · Cochrane | no estimate extracted | 2 studies · 320 participants | Ungraded |
Thyrotropin‐releasing hormone tartrate vs placebo Longer‐term burdens (minimum 1 month) (for example demands on caregivers, frequency of tests, restrictions on lifestyle) · people with speech disorder resulting from hereditary ataxia Treatment for speech disorder in Friedreich ataxia and other hereditary ataxia syndromes (2014) · Cochrane | no estimate extracted | 0 studies · 0 participants | Ungraded |
Thyrotropin‐releasing hormone tartrate vs placebo Economic outcomes · people with speech disorder resulting from hereditary ataxia Treatment for speech disorder in Friedreich ataxia and other hereditary ataxia syndromes (2014) · Cochrane | no estimate extracted | 0 studies · 0 participants | Ungraded |
Varenicline vs placebo Short‐term (1 week) percentage change (improvement) in overall speech production · people with speech disorder resulting from hereditary ataxia Treatment for speech disorder in Friedreich ataxia and other hereditary ataxia syndromes (2014) · Cochrane | no estimate extracted | 0 studies · 0 participants | Ungraded |
Varenicline vs placebo Short‐term (1 week) change in isolated movement, objective and subjective measures of speech production SARA. Scale from: 0 to 6. Higher scores indicate more severe speech disorder. · people with speech disorder resulting from hereditary ataxia Treatment for speech disorder in Friedreich ataxia and other hereditary ataxia syndromes (2014) · Cochrane | no estimate extracted | 1 study · 13 participants | Very low |
Varenicline vs placebo Short‐term (1 week) change in quality of life scores related to communication as measured by validated communication assessments · people with speech disorder resulting from hereditary ataxia Treatment for speech disorder in Friedreich ataxia and other hereditary ataxia syndromes (2014) · Cochrane | no estimate extracted | 0 studies · 0 participants | Ungraded |
Varenicline vs placebo Longer‐term (minimum 1 month) change in generic quality of life scores SF‐36 · people with speech disorder resulting from hereditary ataxia Treatment for speech disorder in Friedreich ataxia and other hereditary ataxia syndromes (2014) · Cochrane | no estimate extracted | 1 study · 13 participants | Very low |
Varenicline vs placebo Adverse effects (during study) · people with speech disorder resulting from hereditary ataxia Treatment for speech disorder in Friedreich ataxia and other hereditary ataxia syndromes (2014) · Cochrane | no estimate extracted | 1 study · 18 participants | Ungraded |
Hydroxytryptophan vs placebo Short‐term (within 1 month) change in isolated movement, objective and subjective measures of speech production Wessel 1995: Mean syllable duration during rapid‐syllable repetition task. Scale from: 1 to 500. Shorter durations are better. · people with speech disorder resulting from hereditary ataxias Treatment for speech disorder in Friedreich ataxia and other hereditary ataxia syndromes (2014) · Cochrane | no estimate extracted | 4 participants | Very low |
Varenicline vs placebo Longer‐term burdens (minimum 1 month) (for example, demands on caregivers, frequency of tests, restrictions on lifestyle) · people with speech disorder resulting from hereditary ataxia Treatment for speech disorder in Friedreich ataxia and other hereditary ataxia syndromes (2014) · Cochrane | no estimate extracted | 0 studies · 0 participants | Ungraded |
Varenicline vs placebo Economic outcomes · people with speech disorder resulting from hereditary ataxia Treatment for speech disorder in Friedreich ataxia and other hereditary ataxia syndromes (2014) · Cochrane | no estimate extracted | 0 studies · 0 participants | Ungraded |
Riluzole vs placebo Short‐term (1 week) percentage change (improvement) in overall speech production · people with speech disorder resulting from hereditary ataxias Treatment for speech disorder in Friedreich ataxia and other hereditary ataxia syndromes (2014) · Cochrane | no estimate extracted | 0 studies · 0 participants | Ungraded |
Riluzole vs placebo Short‐term (within 1 month) change in isolated movement, objective and subjective measures of speech production ICARS. Scale from: 0 to 8. Higher scores indicate more severe speech disorder. · people with speech disorder resulting from hereditary ataxias Treatment for speech disorder in Friedreich ataxia and other hereditary ataxia syndromes (2014) · Cochrane | no estimate extracted | 1 study · 38 participants | Low |
Riluzole vs placebo Short‐term (within 1 month) change in quality of life scores related to communication as measured by validated communication assessments · people with speech disorder resulting from hereditary ataxias Treatment for speech disorder in Friedreich ataxia and other hereditary ataxia syndromes (2014) · Cochrane | no estimate extracted | 0 studies · 0 participants | Ungraded |
Riluzole vs placebo Longer‐term (minimum 1 month) change in generic quality of life scores · people with speech disorder resulting from hereditary ataxias Treatment for speech disorder in Friedreich ataxia and other hereditary ataxia syndromes (2014) · Cochrane | no estimate extracted | 0 studies · 0 participants | Ungraded |
Riluzole vs placebo Adverse effects (during study) · people with speech disorder resulting from hereditary ataxias Treatment for speech disorder in Friedreich ataxia and other hereditary ataxia syndromes (2014) · Cochrane | no estimate extracted | 1 study · 38 participants | Ungraded |
Riluzole vs placebo Longer‐term burdens (minimum 1 month) (for example, demands on caregivers, frequency of tests, restrictions on lifestyle) · people with speech disorder resulting from hereditary ataxias Treatment for speech disorder in Friedreich ataxia and other hereditary ataxia syndromes (2014) · Cochrane | no estimate extracted | 0 studies · 0 participants | Ungraded |
Riluzole vs placebo Economic outcomes · people with speech disorder resulting from hereditary ataxias Treatment for speech disorder in Friedreich ataxia and other hereditary ataxia syndromes (2014) · Cochrane | no estimate extracted | 0 studies · 0 participants | Ungraded |
Idebenone vs placebo Short‐term (1 week) percentage change (improvement) in overall speech production · people with speech disorder resulting from hereditary ataxias Treatment for speech disorder in Friedreich ataxia and other hereditary ataxia syndromes (2014) · Cochrane | no estimate extracted | 0 studies · 0 participants | Ungraded |
Hydroxytryptophan vs placebo Short‐term (within 1 month) change in quality of life scores related to communication as measured by validated communication assessments · people with speech disorder resulting from hereditary ataxias Treatment for speech disorder in Friedreich ataxia and other hereditary ataxia syndromes (2014) · Cochrane | no estimate extracted | 0 studies · 0 participants | Ungraded |
Idebenone vs placebo Short‐term (within 1 month) change in isolated movement, objective and subjective measures of speech production ICARS, FARS · people with speech disorder resulting from hereditary ataxias Treatment for speech disorder in Friedreich ataxia and other hereditary ataxia syndromes (2014) · Cochrane | no estimate extracted | 2 studies · 117 participants | Very low |
Idebenone vs placebo Longer‐term (minimum 1 month) change in generic quality of life scores · people with speech disorder resulting from hereditary ataxias Treatment for speech disorder in Friedreich ataxia and other hereditary ataxia syndromes (2014) · Cochrane | no estimate extracted | 0 studies · 0 participants | Ungraded |
Idebenone vs placebo Adverse effects (during study) · people with speech disorder resulting from hereditary ataxias Treatment for speech disorder in Friedreich ataxia and other hereditary ataxia syndromes (2014) · Cochrane | no estimate extracted | 2 studies · 118 participants | Ungraded |
Idebenone vs placebo Longer‐term burdens (minimum 1 month) (for example, demands on caregivers, frequency of tests, restrictions on lifestyle) · people with speech disorder resulting from hereditary ataxias Treatment for speech disorder in Friedreich ataxia and other hereditary ataxia syndromes (2014) · Cochrane | no estimate extracted | 0 studies · 0 participants | Ungraded |
Idebenone vs placebo Economic outcomes · people with speech disorder resulting from hereditary ataxias Treatment for speech disorder in Friedreich ataxia and other hereditary ataxia syndromes (2014) · Cochrane | no estimate extracted | 0 studies · 0 participants | Ungraded |
Physiotherapy and occupational therapy vs placebo Short‐term (1 week) percentage change (improvement) in overall speech production · people with speech disorder resulting from hereditary ataxias Treatment for speech disorder in Friedreich ataxia and other hereditary ataxia syndromes (2014) · Cochrane | no estimate extracted | 0 studies · 0 participants | Ungraded |
Physiotherapy and occupational therapy vs placebo Short‐term (1 week) change in isolated movement, objective and subjective measures of speech production SARA. Scale from: 0 to 6. Higher scores indicate more severe speech disorder. · people with speech disorder resulting from hereditary ataxias Treatment for speech disorder in Friedreich ataxia and other hereditary ataxia syndromes (2014) · Cochrane | no estimate extracted | 1 study · 42 participants | Very low |
Physiotherapy and occupational therapy vs placebo Short‐term (1 week) change in quality of life scores related to communication as measured by validated communication assessments Functional Independence Measure (total). Scale from: 0 to 126. Higher scores indicate less disability · people with speech disorder resulting from hereditary ataxias Treatment for speech disorder in Friedreich ataxia and other hereditary ataxia syndromes (2014) · Cochrane | no estimate extracted | 1 study · 42 participants | Very low |
Physiotherapy and occupational therapy vs placebo Longer‐term (minimum 1 month) change in generic quality of life scores · people with speech disorder resulting from hereditary ataxias Treatment for speech disorder in Friedreich ataxia and other hereditary ataxia syndromes (2014) · Cochrane | no estimate extracted | 0 studies · 0 participants | Ungraded |
Physiotherapy and occupational therapy vs placebo Adverse effects (during study) · people with speech disorder resulting from hereditary ataxias Treatment for speech disorder in Friedreich ataxia and other hereditary ataxia syndromes (2014) · Cochrane | no estimate extracted | 1 study · 42 participants | Ungraded |
Hydroxytryptophan vs placebo Longer‐term (minimum 1 month) change in generic quality of life scores · people with speech disorder resulting from hereditary ataxias Treatment for speech disorder in Friedreich ataxia and other hereditary ataxia syndromes (2014) · Cochrane | no estimate extracted | 0 studies · 0 participants | Ungraded |
Physiotherapy and occupational therapy vs placebo Longer‐term burdens (minimum 1 month) (for example, demands on caregivers, frequency of tests, restrictions on lifestyle) · people with speech disorder resulting from hereditary ataxias Treatment for speech disorder in Friedreich ataxia and other hereditary ataxia syndromes (2014) · Cochrane | no estimate extracted | 0 studies · 0 participants | Ungraded |
Physiotherapy and occupational therapy vs placebo Economic outcomes · people with speech disorder resulting from hereditary ataxias Treatment for speech disorder in Friedreich ataxia and other hereditary ataxia syndromes (2014) · Cochrane | no estimate extracted | 0 studies · 0 participants | Ungraded |
Betamethasone vs placebo Short‐term (1 week) percentage change (improvement) in overall speech production · people with speech disorder resulting from hereditary ataxias Treatment for speech disorder in Friedreich ataxia and other hereditary ataxia syndromes (2014) · Cochrane | no estimate extracted | 0 studies · 0 participants | Ungraded |
Betamethasone vs placebo Short‐term (within 1 month) change in isolated movement, objective and subjective measures of speech production ICARS. Scale from: 0 to 8. Higher scores indicate more severe disorder. · people with speech disorder resulting from hereditary ataxias Treatment for speech disorder in Friedreich ataxia and other hereditary ataxia syndromes (2014) · Cochrane | no estimate extracted | 13 participants | Moderate |
Betamethasone vs placebo Short‐term (within 1 month) change in quality of life scores related to communication as measured by validated communication assessments · people with speech disorder resulting from hereditary ataxias Treatment for speech disorder in Friedreich ataxia and other hereditary ataxia syndromes (2014) · Cochrane | no estimate extracted | 0 studies · 0 participants | Ungraded |
Betamethasone vs placebo Longer‐term (minimum 1 month) change in generic quality of life scores Child Health Questionnaires · people with speech disorder resulting from hereditary ataxias Treatment for speech disorder in Friedreich ataxia and other hereditary ataxia syndromes (2014) · Cochrane | no estimate extracted | 0 studies · 0 participants | Ungraded |
Betamethasone vs placebo Adverse effects (during study) · people with speech disorder resulting from hereditary ataxias Treatment for speech disorder in Friedreich ataxia and other hereditary ataxia syndromes (2014) · Cochrane | no estimate extracted | 13 participants | Ungraded |
Betamethasone vs placebo Longer‐term burdens (minimum 1 month) (for example, demands on caregivers, frequency of tests, restrictions on lifestyle) · people with speech disorder resulting from hereditary ataxias Treatment for speech disorder in Friedreich ataxia and other hereditary ataxia syndromes (2014) · Cochrane | no estimate extracted | 0 studies · 0 participants | Ungraded |
Betamethasone vs placebo Economic outcomes · people with speech disorder resulting from hereditary ataxias Treatment for speech disorder in Friedreich ataxia and other hereditary ataxia syndromes (2014) · Cochrane | no estimate extracted | 0 studies · 0 participants | Ungraded |
High‐dose vs low‐dose coenzyme Q10 and vitamin E Short‐term (1 week) percentage change (improvement) in overall speech production · people with speech disorder resulting from hereditary ataxia Treatment for speech disorder in Friedreich ataxia and other hereditary ataxia syndromes (2014) · Cochrane | no estimate extracted | 0 studies · 0 participants | Ungraded |
Hydroxytryptophan vs placebo Adverse effects (during the study) · people with speech disorder resulting from hereditary ataxias Treatment for speech disorder in Friedreich ataxia and other hereditary ataxia syndromes (2014) · Cochrane | no estimate extracted | 2 studies · 65 participants | Ungraded |
High‐dose vs low‐dose coenzyme Q10 and vitamin E Short‐term (within 1 month) change in isolated movement, objective and subjective measures of speech production Cooper 2008 reported 3 speech measures: ICARS speech subscale. Scale from: 0 to 8. Higher scores indicate greater clinical severity Syl... · people with speech disorder resulting from hereditary ataxia Treatment for speech disorder in Friedreich ataxia and other hereditary ataxia syndromes (2014) · Cochrane | no estimate extracted | 1 study · 43 participants | Low |
High‐dose vs low‐dose coenzyme Q10 and vitamin E Short‐term (within 1 month) change in quality of life scores related to communication as measured by validated communication assessments · people with speech disorder resulting from hereditary ataxia Treatment for speech disorder in Friedreich ataxia and other hereditary ataxia syndromes (2014) · Cochrane | no estimate extracted | 0 studies · 0 participants | Ungraded |
High‐dose vs low‐dose coenzyme Q10 and vitamin E Longer‐term (minimum 1 month) change in generic quality of life scores · people with speech disorder resulting from hereditary ataxia Treatment for speech disorder in Friedreich ataxia and other hereditary ataxia syndromes (2014) · Cochrane | no estimate extracted | 0 studies · 0 participants | Ungraded |